Pirlimycin Chemical Properties

Boiling point:

643.9±55.0 °C(Predicted)

Density 

1.31

storage temp. 

Store at -20°C

solubility 

Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide

form 

solid

pka

12.88±0.70(Predicted)

Stability:

Hygroscopic

Pirlimycin Usage And Synthesis

Uses

Pirlimycin is a semi-synthetic lincosamide prepared from clindamycin by hydrolysing the propyl N-methylproline and re-annealing a 4-ethylpipecolic acid. Pirlimycin is more hydrophobic than clindamycin and is more potent against a number of important pathogens. Like other members of the lincosamide family, pirlimycin is a broad spectrum antibiotic with activity against anaerobic bacteria and protozoans. Pirlimycin acts by binding to the 23S ribosomal subunit, blocking protein synthesis. Pirlimycin has been less extensively researched than the older lincosamides.

Biological Activity

pirlimycin, a lincosamide antibiotic, is effective against gram-positive bacteria, including staphylococcus, bacteroides, streptococcus, and plasmodium. it functions via inhibiting protein synthesis in bacteria by inducing premature dissociation of the peptidyl-trna from the ribosome.

Veterinary Drugs and Treatments

Pirlimycin mastitis tubes are indicated for the treatment of clinical and subclinical mastitis caused by susceptible organisms in lactating dairy cattle.

in vitro

pirlimycin showed activity against helicobacter pylori with a minimal inhibitory concentration [mic] 50 of 4 μg/ml and an mic90 of 64 μg/ml [1].

in vivo

cows were treated with 50 mg of pirlimycin via two intramammary infusions per quarter at a 24-hour interval (2-day) for 2, 5, or 8 days. pirlimycin showed antibiotic therapy against environmental streptococcus spp and staphylococcus aureus intramammary individual and combined infections [1]. specifically, pirlimycin cured environmental streptococcus spp infections in 66.7% (14/21), 85% (17/20), 100% (14/14) in the 2-day group, 5-day group and 8-day group, respectively. s. aureus infections were cured by the treatment of pirlimycin in 13.3% (2/15), 31.3% (5/16), 83.3% (5/6) in the 2-day group, 5-day group and 8-day group, respectively. furthermore, s. aureus, s. dysgalactiae subsp dysgalactiae, and enterococcus spp intramammary infections were eliminated by the extended treatment of pirlimycin in 8-day group [2].

References

[1]. westblom, t., midkiff, b., & czinn, s. in vitro susceptibility ofhelicobacter pylori to trospectomycin, pirlimycin (u-57930e), mirincamycin (u-24729a) and n-demethyl clindamycin (u-26767a). european journal of clinical microbiology & infectious diseases. 1993; 12(7): 560-562.
[2]. b. e. gillespie, h. moorehead, p. lunn, h. h. dowlen, d. l. johnson, k. c. lamar, m. j. lewis, s. j. ivey, j. w. hallberg, s. t. chester, and s. p. oliver. efficacy of extended pirlimycin hydrochloride therapy for treatment of environmental streptococcus spp and staphylococcus aureus intramammary infections in lactating dairy cows. veterinary therapeutics. 2002; 3(4): 373-80.

Pirlimycin(79548-73-5)Related Product Information

• Rofecoxib
• PLATINUM(Ⅳ) OXIDE
• Pirlimycin
• METHYL-(TETRAHYDRO-PYRAN-2-YLMETHYL)-AMINE HYDROCHLORIDE
• C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE HYDROCHLORIDE
• METHYL-(TETRAHYDRO-PYRAN-2-YLMETHYL)-AMINE
• N-ethylpiperidine-2-carboxamide
• N-methylpiperidine-2-carboxamide
• CHEMBRDG-BB 4015227
• Pipecolamide